Reviews on new drug targets in age-related disorders . Part II / / Paul C. Guest, editor

• Pubblicazione: Cham, Switzerland : , : Springer, , [2021]; ©2021
• Descrizione fisica: 1 online resource (274 pages)
• Disciplina: 615.7
• Soggetto topico: Drug targeting; Malalties de les persones grans; Dianes farmacològiques
• Soggetto genere / forma: Llibres electrònics
• Persona (resp. second.): GuestPaul C.
• Nota di contenuto: Intro -- Preface -- Contents -- 1: New Therapeutic Approaches and Biomarkers for Increased Healthspan -- 1.1 Introduction -- 1.2 Body Composition -- 1.2.1 Adiposity -- 1.2.2 Muscle Mass -- 1.2.3 Therapeutic Approaches Targeting Body Composition -- 1.2.3.1 Resistance Exercise -- 1.2.3.2 Dietary Methods -- 1.2.3.3 Pharmaceuticals and Natural Compounds -- 1.2.3.4 Combination Approaches -- 1.3 Biomarkers -- 1.3.1 Physical Function and Body Composition -- 1.3.2 Circulating Molecular Biomarkers -- 1.3.3 Genes -- 1.3.3.1 FOXO -- 1.3.3.2 APOE -- 1.3.3.3 KL -- 1.3.3.4 ACE -- 1.3.3.5 IL-6 -- 1.3.3.6 Genetic Networks -- 1.4 Conclusions and Future Perspectives -- References -- 2: Targeting Cancer Metabolism and Current Anti-Cancer Drugs -- 2.1 Introduction -- 2.2 Glycolysis -- 2.2.1 Hexokinase -- 2.2.2 Pyruvate Kinase -- 2.2.3 Lactate Dehydrogenase-A -- 2.2.4 Monocarboxylate Transporters (MCTs) -- 2.3 Mitochondrial Metabolism -- 2.3.1 Pyruvate Dehydrogenase Kinase -- 2.3.2 TCA Cycle -- 2.3.3 Oxidative Phosphorylation -- 2.4 Glutaminolysis -- 2.4.1 Glutaminase (GLS) -- 2.5 De Novo Fatty Acid Synthesis -- 2.5.1 ATP-Citrate Lyase -- 2.5.2 Acetyl-CoA Carboxylase -- 2.5.3 Fatty Acid Synthase -- 2.6 Conclusion and Future Perspectives -- References -- 3: A Review of Monoclonal Antibody-Based Treatments in Non-small Cell Lung Cancer -- 3.1 Introduction -- 3.2 Targeted Therapies and their Approved Antibodies -- 3.2.1 Epidermal Growth Factor Receptor (EGFR) -- 3.2.1.1 Cetuximab -- 3.2.1.2 Nimotuzumab -- 3.2.1.3 Matuzumab -- 3.2.1.4 Necitumumab -- 3.2.1.5 Panitumumab -- 3.2.2 Vascular Endothelial Growth Factor (VEGF) -- 3.2.2.1 Bevacizumab -- 3.2.2.2 Ramucirumab -- 3.2.3 PD-1 and PD Ligands 1 and 2 (PD-L1 and L2) -- 3.2.3.1 Pembrolizumab -- 3.2.3.2 Nivolumab -- 3.2.3.3 Atezolizumab -- 3.2.3.4 Durvalumab. ; 3.2.3.5 Avelumab -- 3.2.4 IGF-1R -- 3.2.4.1 Figitumumab -- 3.2.5 RANKL -- 3.2.5.1 Denosumab -- 3.2.6 HGF -- 3.2.6.1 Ficlatuzumab -- 3.2.6.2 Rilotumumab -- 3.2.7 CTLA-4 -- 3.2.7.1 Ipilimumab -- 3.2.7.2 Tremelimumab -- 3.2.8 Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) Receptor 2 (TR-2) or Death Receptor 5 (DR5) -- 3.2.8.1 Conatumumab -- 3.3 Conclusions -- References -- 4: Parkinson's Disease and Impairment in Mitochondrial Metabolism: A Pathognomic Signature -- 4.1 Introduction -- 4.2 Impaired Mitochondrial Metabolism Etiologies -- 4.2.1 Mutations in the OxPhos System -- 4.2.2 Defects in Complex 1 and PD Prognosis: A Pathognomic Signature -- 4.2.3 Intracellular ROS -- 4.2.4 Impaired Calcium Balance -- 4.2.5 Mitochondrial ETC Inhibitors and Environmental Toxicants -- 4.2.6 Increased Fat Diet Uptake -- 4.3 PD and Perturbed Mitochondrial Metabolism -- 4.4 Conclusions and Future Perspectives -- References -- 5: Targeted Treatment of Age-Related Fibromyalgia with Supplemental Coenzyme Q10 -- 5.1 Introduction -- 5.2 Pathogenesis of Fibromyalgia -- 5.3 Fibromyalgia and Aging -- 5.4 Nutritional Supplementation and Aging -- 5.5 CoQ10 -- 5.6 Clinical Studies on CoQ10 Supplementation in Fibromyalgia -- 5.7 Safety and Bioavailability of CoQ10 -- 5.8 Conclusions -- References -- 6: Immunoregulatory Effects of Tolerogenic Probiotics in Multiple Sclerosis -- 6.1 Introduction -- 6.2 MS and the Immune System -- 6.2.1 Th1 and Th17 in MS -- 6.2.2 Th9 and Th22 in MS -- 6.2.3 CD8+ T Cells and B Cells in MS -- 6.2.4 T Regulatory (Treg) and Th2 Cells in MS -- 6.3 Risk Factors of MS -- 6.4 Therapeutics Approaches for MS -- 6.4.1 Probiotics and Autoimmune Diseases -- 6.4.2 Cross-Talk of Multiple Sclerosis and Microbiota -- 6.4.3 Modulatory Effects of Tolerogenic Probiotics on CNS. ; 6.4.4 Modulatory Effects of Tolerogenic Probiotics on Treg Cells -- 6.4.5 Modulatory Effects of Tolerogenic Probiotics on Th1 and Th17 -- 6.5 Concluding Remarks -- References -- 7: Multifaceted Roles of Long Non-coding RNAs in Head and Neck Cancer -- 7.1 Introduction -- 7.2 Structure and Characteristics of lncRNAs -- 7.3 lncRNAs Associated with Tumorigenesis and Development of Head and Neck Cancer (HNC) -- 7.4 lncRNAs Associated with Invasion and Metastasis of HNC -- 7.5 lncRNAs Associated with Treatment Resistance in HNC -- 7.6 Prognostic Role of lncRNAs in HNC -- 7.7 Conclusions -- References -- 8: A Systematic Review on the Genotoxic Effects of Selective Serotonin Reuptake Inhibitors -- 8.1 Introduction -- 8.2 Methods -- 8.2.1 Literature Search Strategy -- 8.2.2 Inclusion and Exclusion Criteria -- 8.2.3 Data Extraction -- 8.3 Results -- 8.3.1 Literature Search -- 8.3.2 Citalopram -- 8.3.3 Escitalopram -- 8.3.4 Fluoxetine -- 8.3.5 Fluvoxamine -- 8.3.6 Paroxetine -- 8.3.7 Sertraline -- 8.4 Discussion -- 8.5 Conclusions -- References -- 9: Toward a New Era for the Management of Circulating Tumor Cells -- 9.1 Introduction -- 9.2 Historical Background -- 9.3 Detection Methods -- 9.3.1 Biological Properties -- 9.3.1.1 Density Gradient Centrifugation -- 9.3.1.2 Filtration -- 9.3.2 Physical Properties -- 9.3.2.1 Negative Selection -- 9.3.2.2 Positive Selection -- 9.4 Research of Circulating Tumor Cells in Several Types of Cancers -- 9.4.1 Breast Cancer -- 9.4.2 Colorectal Cancer -- 9.4.3 Lung Cancer -- 9.4.4 Prostate Cancer -- 9.4.5 Melanoma -- 9.4.6 Sarcomas -- 9.4.7 Head and Neck Cancer -- 9.5 Clinical Applications and Limitations -- 9.6 Conclusion -- References -- 10: Telomerase: A Target for Therapeutic Effects of Curcumin in Cancer -- 10.1 Introduction -- 10.2 In Vitro Studies on Telomerase Inhibition. ; 10.3 In Vivo Studies -- 10.4 Conclusions -- References -- 11: Aspirin as a Potential Geroprotector: Experimental Data and Clinical Evidence -- 11.1 Introduction -- 11.2 Mechanisms of Action -- 11.3 Lifespan Extension in Model Organisms -- 11.3.1 Caenorhabditis elegans -- 11.3.2 Drosophila melanogaster -- 11.3.3 Rodents -- 11.4 Health Benefits of Aspirin: Evidence from Clinical Trials -- 11.4.1 Aspirin and CVD Prevention in Elderly -- 11.4.2 Anti-Cancer Effects of Aspirin -- 11.4.3 Anti-inflammatory Properties of Aspirin -- 11.4.4 Aspirin and Cognitive Function -- 11.5 Adverse Effects of Aspirin -- 11.5.1 Aspirin and Risk of Bleedings -- 11.5.2 Low-Dose Aspirin on Intracranial Hemorrhage (ICH) and Cerebral Microbleeds -- 11.5.3 Adverse Effects of Aspirin in Elderly Patients Having Surgical Procedures -- 11.5.4 Aspirin and Potential Drug-Drug Interactions -- 11.6 Conclusions and Future Directions -- References -- 12: Targeting Stem Cells in Chronic Inflammatory Diseases -- 12.1 Introduction -- 12.2 Mesenchymal Stem Cells -- 12.3 Dysregulation of MSCs' Immunomodulatory Properties -- 12.4 Methodological Considerations in the Interpretation of Intervention Strategy Outcomes -- 12.5 Interventions -- 12.5.1 Pharmacological Blocking of NFкB Signalling -- 12.5.2 Natural Antioxidants and/or Anti-inflammatory Agents -- 12.5.3 Biological Agents -- 12.5.3.1 Microvesicles and Exosomes -- 12.5.3.2 Probiotics: An Emerging Therapeutic Hope? -- 12.6 Conclusion -- References -- 13: Therapeutic Strategies and Nano-Drug Delivery Applications in Management of Aging Alzheimer's Disease -- 13.1 Introduction -- 13.2 Targeting the Amyloid Cascade -- 13.3 Nanomaterials Against Amyloid Diseases -- 13.4 Nanotechnologies for AD Treatment -- 13.4.1 Targeting Androgen and Estrogen NPs -- 13.4.2 Polymeric Nanoparticles. ; 13.4.3 Inorganic Nanoparticles -- 13.4.4 Mitochondrial Targeting -- 13.5 Targets for Future Drugs -- 13.6 Conclusion, Challenges, and Future Perspectives -- References -- 14: Psychometric Evaluation of Stress in 17,414 Critical Care Unit Nurses: Effects of Age, Gender, and Working Conditions -- 14.1 Introduction -- 14.2 Methods -- 14.2.1 Design, Setting, and Procedures -- 14.2.2 Ethical Considerations -- 14.2.3 Sample Size -- 14.2.4 Measurements -- 14.2.5 Statistical Analyses -- 14.3 Results -- 14.3.1 Content Validity -- 14.3.2 Construct Validity -- 14.3.3 Reliability -- 14.3.4 Convergent Validity -- 14.3.5 Discriminate Validity (the Fornell-Larcker Criterion) -- 14.3.6 Relationship Between Stress Components and Background Variables -- 14.4 Discussion -- 14.5 Conclusion -- References -- 15: Targeting Age-Related Neurodegenerative Diseases by AAV-Mediated Gene Therapy -- 15.1 Introduction -- 15.2 AAV-Based Gene Therapy -- 15.3 Optimizing AAV Capsids for Efficient CNS Transduction -- 15.4 AAV-Based Gene Therapy for AD, PD, and ALS: Highlights from the Clinic -- 15.4.1 Alzheimer's Disease (AD) -- 15.4.2 Parkinson's Disease (PD) -- 15.4.3 Amyotrophic Lateral Sclerosis (ALS) -- 15.5 Conclusions -- References -- 16: Is Adipose Tissue the Fountain of Youth? The Impact of Adipose Stem Cell Aging on Metabolic Homeostasis, Longevity, and Cell-Based Therapies -- 16.1 Introduction -- 16.2 The Effects of Chronological Aging on ASC Biology and Function -- 16.2.1 Age-Induced ASC Senescence -- 16.2.1.1 Senescence Mechanisms: A Brief Overview -- 16.2.1.2 Markers of Senescence -- 16.2.1.3 Characterization of Age-Associated Senescence in ASCs -- 16.2.2 Downregulation of the Adipogenic Gene Program -- 16.2.3 Age, Senescence, and Inflammation in ASCs. ; 16.2.4 The Role of ASCs in the Age-Related Loss of Lipid Storage Capacity in Adipose Tissue.
• Titolo autorizzato: Reviews on new drug targets in age-related disorders
• ISBN: 3-030-55035-4
• Formato: Materiale a stampa
• Livello bibliografico: Monografia
• Lingua di pubblicazione: Inglese
• Record Nr.: 9910483072203321
• Lo trovi qui: Univ. Federico II
• Serie: Advances in Experimental Medicine and Biology